Healius (ASX:HLS) has completed its operating & strategic review culminating in the sale of its Lumus Imaging unit for AU$965 million, according to a Thursday Australian bourse filing.
The sale to Affinity Equity Partners is expected to complete on May 1 and its proceeds will be used to pay shareholders a special dividend of AU$0.41 per share.
After the Lumus sale, the company said it would save AU$15 million to AU$20 million in costs by cutting unallocated corporate costs and pathology expenses.
The company's shares were up 13% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.